These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1716 related items for PubMed ID: 36044198

  • 1. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, Compton WM.
    JAMA Psychiatry; 2022 Oct 01; 79(10):981-992. PubMed ID: 36044198
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Overdose, Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose.
    Jones CM, Shoff C, Blanco C, Losby JL, Ling SM, Compton WM.
    JAMA Intern Med; 2024 Aug 01; 184(8):954-962. PubMed ID: 38884975
    [Abstract] [Full Text] [Related]

  • 4. Opioid Overdose After Medication for Opioid Use Disorder Initiation Following Hospitalization or ED Visit.
    Weiner SG, Little K, Yoo J, Flores DP, Hildebran C, Wright DA, Ritter GA, El Ibrahimi S.
    JAMA Netw Open; 2024 Jul 01; 7(7):e2423954. PubMed ID: 39037812
    [Abstract] [Full Text] [Related]

  • 5. Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study.
    Livingston NA, Sarpong A, Sistad R, Roth C, Banducci AN, Simpson T, Hyde J, Davenport M, Weisberg R.
    J Subst Use Addict Treat; 2024 Jan 01; 156():209188. PubMed ID: 37866437
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S, Sun L, Vakkalanka JP.
    Am J Emerg Med; 2024 Aug 01; 82():52-56. PubMed ID: 38795424
    [Abstract] [Full Text] [Related]

  • 7. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
    Bello JK, Xu KY, Salas J, Bedrick BS, Grucza RA.
    J Gen Intern Med; 2024 Jun 01; 39(8):1342-1348. PubMed ID: 38424347
    [Abstract] [Full Text] [Related]

  • 8. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM.
    JAMA Netw Open; 2020 Feb 05; 3(2):e1920622. PubMed ID: 32022884
    [Abstract] [Full Text] [Related]

  • 9. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR, Rao N, Domino ME.
    Addiction; 2022 Nov 05; 117(11):2855-2863. PubMed ID: 35194878
    [Abstract] [Full Text] [Related]

  • 10. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
    Hammerslag LR, Mack A, Chandler RK, Fanucchi LC, Feaster DJ, LaRochelle MR, Lofwall MR, Nau M, Villani J, Walsh SL, Westgate PM, Slavova S, Talbert JC.
    JAMA Netw Open; 2023 Oct 02; 6(10):e2336914. PubMed ID: 37851446
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
    Burns M, Tang L, Chang CH, Kim JY, Ahrens K, Allen L, Cunningham P, Gordon AJ, Jarlenski MP, Lanier P, Mauk R, McDuffie MJ, Mohamoud S, Talbert J, Zivin K, Donohue J.
    Addiction; 2022 Dec 02; 117(12):3079-3088. PubMed ID: 35652681
    [Abstract] [Full Text] [Related]

  • 13. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA, Davenport M, Head M, Henke R, LeBeau LS, Gibson TB, Banducci AN, Sarpong A, Jayanthi S, Roth C, Camacho-Cook J, Meng F, Hyde J, Mulvaney-Day N, White M, Chen DC, Stein MD, Weisberg R.
    Drug Alcohol Depend; 2022 Dec 01; 241():109678. PubMed ID: 36368167
    [Abstract] [Full Text] [Related]

  • 14. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic.
    Hailu R, Mehrotra A, Huskamp HA, Busch AB, Barnett ML.
    JAMA Netw Open; 2023 Jan 03; 6(1):e2252381. PubMed ID: 36692880
    [Abstract] [Full Text] [Related]

  • 15. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
    Hartung DM, Markwardt S, Johnston K, Geddes J, Baker R, Leichtling G, Hildebran C, Chan B, Cook RR, McCarty D, Ghitza U, Korthuis PT.
    Addict Sci Clin Pract; 2022 Aug 19; 17(1):45. PubMed ID: 35986384
    [Abstract] [Full Text] [Related]

  • 16. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.
    Gibbons JB, McCullough JS, Zivin K, Brown ZY, Norton EC.
    J Subst Use Addict Treat; 2024 Feb 19; 157():209271. PubMed ID: 38135120
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
    Xu KY, Mintz CM, Presnall N, Bierut LJ, Grucza RA.
    JAMA Netw Open; 2022 May 02; 5(5):e2211363. PubMed ID: 35536575
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 86.